[1] Nakamura Takamitsu, Kugiyama Kiyotaka. Triglycerides and remnant particles as risk factors for coronary artery disease. Curr Atheroscler Rep. 2006;8:107-110.
[2] Nakamura Takamitsu, Obata Jun-ei, Hirano Mitsumasa, et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis. 2011;218:163-167.
[3] Joshi P H, Khokhar A A, Massaro J M, et al. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. J Am Heart Assoc. 2016;5(5):e002765.
[4] Faridi Kamil F, Quispe Renato, Martin Seth S, et al. Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. J Clin Lipidol. 2019;13: 634-644.
[5] Varbo Anette, Benn Marianne, Tybjærg-Hansen Anne, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427-436.
[6] Kawakami Akio, Yoshida Masayuki. Remnant lipoproteins and atherogenesis. Atheroscler Thromb. 2005;12: 73-76.
[7] Hattori Sachiko. Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance. J Diabetes Investig. 2018;9:870-874.
[8] Yoshida Hiroshi, Hirowatari Yuji, Kurosawa Hideo, et al. Estimation of lipoprotein profile in patients with type II diabetes and its relevance to remnant lipoprotein cholesterol levels. Atherosclerosis. 2012;222:541-544.
[9] Xu Xiangyu, Pandit Ram Udgar, Han Le, et al. Remnant Lipoprotein Cholesterol Independently Associates With In-Stent Restenosis After Drug-Eluting Stenting for Coronary Artery Disease. Angiology. 2019;70:853-859.
[10] Mazzone T, Chait A, Plutzky J. Addressing cardiovascular disease risk in diabetes: insights from mechanistic studies. Lancet. 2008; 24(371):1800-1809.
[11] Mach François, Baigent Colin, Catapano Alberico L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;00:1-78.
[12] Fujihara Yuki, Nakamura Takamitsu, Horikoshi Takeo, et al. Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL. Circ J. 2019;83:1302-1308.
[13] Shigemasa Tani, Tsukasa Yagi, Wataru Atsumi, Kenji Kawauchi, Rei Matsuo and Atsushi Hirayama. Relation between low‑density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2017;16:123.
[14] Ye Xiaofeng, Kong Wen, Zafar Mohammad Ishraq, et al. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019;18:48.
[15] McNamara J R, Shah P K, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154:229-236.
[16] Lamon-Fava Stefania, Herrington David M, Reboussin David M, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008;28:575-579.
[17] Balling Mie, Langsted Anne, Afzal Shoaib, et al. A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals. Atherosclerosis. 2019;286:97-104.
[18] Izumida T, Nakamura Y, Hino Y, Ishikawa S. Combined Effect of Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) and Remnant-Like Particle Cholesterol (RLP-C) on Low-Grade Inflammation. J Atheroscler Thromb. 2019;29:1-12.
[19] Varbo Anette, Benn Marianne, Tybjærg-Hansen Anne, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128: 1298-1309.
[20] Kugiyama K, Doi H, Takazoe K et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999;99:2858-2860.
[21] Fukushima H, Kugiyama K, Sugiyama S, et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol. 2001;88:1370-1373.
[22] Fukushima Hironobu, Sugiyama Seigo, Honda Osamu, et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol. 2004;43:2219-2224.
[23] Li Ling, Sawamura Tatsuya, Renier Geneviève. Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes. 2003;52:1843-1850.
[24] Shin Hwa Kyoung, Kim Yong Ki, Kim Ki Young et al. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation. 2004;109:1022-1028.
[25] Aramaki Yo, Mitsuoka Hirokazu, Toyohara Masako, et al. Lectin-like oxidized LDL receptor-1 (LOX-1) acts as a receptor for remnant-like lipoprotein particles (RLPs) and mediates RLP-induced migration of vascular smooth muscle cells. Atherosclerosis. 2008;198:272-279.
[26] Brinkley Tina E, Kume Noriaki, Mitsuoka Hirokazu, et al. Elevated soluble lectin-like oxidized LDL receptor-1 (sLOX-1) levels in obese postmenopausal women. Obesity. 2008;16:1454-1456.
[27] Zheng Qin, Kuo Zhou, Yue ping Li, Jian long Wang, Wan jun Cheng, Cheng ping Hu, Chao Shi, Hua He, Yu jie Zhou. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study. Cardiovasc Diabetol. 2019;18:11.
[28] Filipa Mascarenhas Melo, Daniela Marado, Filipe Palavra, José Sereno, Álvaro Coelho, Rui Pinto, Edite Teixeira Lemos, Frederico Teixeira, Flávio Reis. Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovasc Diabetol. 2013;12:61.
[29] Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
[30] Costanian Christy, McCague Hugh, Edgell Heather, et al. Changes in adiposity and other factors in relation to age at natural menopause: analyses from the coronary artery risk development (CARDIA) study. Menopause. 2019;26:162-171.
[31] Varbo Anette, Benn Marianne, Smith George Davey, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res. 2015;116:665-673.
[32] Savonitto Stefano, Colombo Delia, Franco Nicoletta, et al. Age at Menopause and Extent of Coronary Artery Disease Among Postmenopausal Women with Acute Coronary Syndromes. Am J Med. 2016;129:1205-1212.
[33] Savonitto Stefano, Morici Nuccia, Franco Nicoletta, et al. Age at menopause, extent of coronary artery disease and outcome among postmenopausal women with acute coronary syndromes. Int J Cardiol. 2018;259:8-13.
[34] Bernelot Moens Sophie J, Schnitzler Gavin R, Nickerson Moriah, et al. Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation. 2012;126:1993-2004.
[35] Lamon-Fava Stefania, Herrington David M, Horvath Katalin V, et al. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metab Clin Exp. 2010;59:1794-1800.
[36] Bittner Vera, Tripputi Mark, Hsia Judith, et al. Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women's Angiographic Vitamin & Estrogen Trial. Am Heart J. 2004;148: 293-299.
[37] Lamon-Fava Stefania, Herrington David M, Reboussin David M, et al. Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. Atherosclerosis. 2009;205: 325-330.